toxylact: a04aa01 ondasetron

The first professional lActological database in the word

This ATC class monograph covers ondansetron (A04AA01) as a 5‑HT3 receptor antagonist with a focused overview of general pharmacology, toxicology and lactation safety for professional use on a web page.medpedia.framar

ATC class and pharmacological profile

A04AA01 comprises the selective serotonin 5‑HT3 receptor antagonist ondansetron, classified among antiemetics acting on the gastrointestinal tract and the chemoreceptor trigger zone (CTZ). Ondansetron inhibits 5‑HT3 receptors centrally in the area postrema (CTZ) and peripherally in vagal afferents of the upper gastrointestinal tract, thereby suppressing acute nausea and vomiting, particularly that induced by cytotoxic chemotherapy and radiotherapy. The drug shows high antiemetic efficacy against acute emesis mediated by serotonin release, with less effect on delayed emesis where other pathways (e.g. substance P) dominate.medpedia.framar

Indications and dosing characteristics

Within class A04AA01, ondansetron is indicated for prevention and treatment of nausea and vomiting associated with chemotherapy and radiotherapy in adults and paediatric patients, and in many jurisdictions also for prevention of postoperative nausea and vomiting (PONV). The Bulgarian source specifies its use “for treatment of patients with nausea and vomiting induced by chemo‑ or radiotherapy”, reflecting the core oncologic indication. Typical adult regimens for highly emetogenic chemotherapy use 8 mg intravenously immediately before cytotoxic treatment or 8 mg orally 1–2 hours beforehand, with possible repeat dosing or combination with corticosteroids according to protocol.medpedia.framar

Toxicological profile

Ondansetron has a relatively favourable safety profile when used at recommended doses, but several toxicological aspects are clinically relevant. Common adverse effects include headache, dizziness, constipation and transient elevations of hepatic transaminases (ASAT, ALAT), alongside occasional cutaneous rashes. At higher exposures or in predisposed patients, ondansetron can prolong the QT interval and has been associated with rare torsades de pointes, particularly when combined with other QT‑prolonging drugs or in patients with electrolyte disturbances, bradyarrhythmias or congenital long QT.medpedia.framar

Dose‑related toxic phenomena may arise in overdose, with manifestations such as severe constipation, visual disturbances, hypotension or arrhythmias, and require supportive management and ECG monitoring. The active substance undergoes extensive hepatic metabolism; consequently, cumulative toxicity risk is higher in significant hepatic impairment, where dosage reduction is recommended and monitoring of liver function and ECG is prudent.medpedia.framar

Drug interactions and risk modifiers

The interaction section linked from the Bulgarian database lists numerous clinically relevant interactions, with 38 classified as strongly clinically significant, 104 as moderately significant and several of minor importance. Although individual pairs are detailed elsewhere, typical high‑risk combinations include other QT‑prolonging agents (e.g. certain antiarrhythmics, antipsychotics), serotonergic drugs that may increase serotonin syndrome risk, and CYP‑modifying agents that can alter ondansetron exposure. Co‑administration with hepatotoxic drugs can potentiate liver enzyme elevations, and combinations with medications causing constipation or ileus can aggravate gastrointestinal motility disorders.medpedia.framar

Lactation and reproductive safety (toxico‑lactological focus)

Data on ondansetron in lactation are more limited than in pregnancy, but the pharmacokinetic properties (moderate molecular weight, high hepatic metabolism, short half‑life) suggest that milk transfer is likely to be low to moderate. Reported clinical use during breastfeeding for short courses, especially around surgery or chemotherapy‑related emesis, has not consistently shown serious adverse effects in nursing infants; however, systematic controlled studies remain scarce, so risk assessment should stay individualized. Potential theoretical risks in breastfed infants include transient sedation, irritability, altered feeding patterns or changes in bowel habits (constipation or diarrhoea), and careful observation of the infant is advisable when the mother receives repeated or high doses.medpedia.framar

In the toxicological‑lactological context, ondansetron A04AA01 would generally be considered a drug where short‑term maternal use may be compatible with breastfeeding under medical supervision, particularly when treating severe nausea that threatens maternal hydration and nutritional status. However, in neonates or preterm infants, and in cases of maternal hepatic disease, a more cautious approach—including dose minimization, timing feeds away from peak plasma levels, or temporary milk expression and discard in extreme scenarios—can reduce exposure. Overall, the benefit‑risk balance often favours controlled use when no safer effective alternative antiemetic is available, but documentation in professional databases should clearly flag QT‑related cardiotoxicity, hepatic effects and interaction burden as key toxicological determinants for lactation risk stratification.medpedia.framar

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.